Attached files
| file | filename |
|---|---|
| EX-3.1 - ENDONOVO THERAPEUTICS, INC. | ex3-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 11, 2019
ENDONOVO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-55453 | 45-2552528 | ||
| (State
or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367
(Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 | ENDV | OTCQB |
Item 3.03 Material Modification to Rights of Security Holders.
On December 11, 2019 a certificate of amendment to the Registrant’s Certificate of Incorporation was filed to affect a one thousand for one reverse stock split (“Reverse Stock Split”). The Registrant has been advised by FINRA that the Reverse Stock Split will become effective on December 20, 2019. For the details of the Reverse Stock Split, the reader is directed to the Certificate of Amendment which is an exhibit hereto.
Item 9.01 Financial Statements and Exhibits.
| (a) | Financial Statements |
None
| (b) | Exhibits |
| 3.1 | Certificate of Amendment affecting Reverse Stock Split |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 18, 2019
| ENDONOVO THERAPEUTICS, INC. | ||
| By: | /s/ Alan Collier | |
Alan Collier Chief Executive Officer | ||